- STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
- Alvotech Announces Closing of Private Debt Financing
- Alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
- Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva
- Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf
- Alvotech Issues New Shares to Holders of Convertible Bonds
- Alvotech kynnir áætlaðar mettekjur og EBITDA framlegð á öðrum ársfjórðungi 2024
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
More ▼
Key statistics
On Tuesday, Alvotech SA (ALVO:ICX) closed at 1,637.50, 39.96% above the 52 week low of 1,170.00 set on Sep 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1,650.00 |
---|---|
High | 1,650.00 |
Low | 1,625.00 |
Bid | 1,635.00 |
Offer | 1,640.00 |
Previous close | 1,650.00 |
Average volume | 93.19k |
---|---|
Shares outstanding | 301.94m |
Free float | 107.75m |
P/E (TTM) | -- |
Market cap | 3.62bn USD |
EPS (TTM) | -2.05 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 16:20 BST.
More ▼